VCYT — VERACYTE, INC.

Nasdaq · Health Care · Health Care Providers & Services · CIK 1384101 ·
Last close
$55.71
Market Cap
$4.45B
52W High
$60.91
52W Low
$31.57
ADV30
1,257,358
Next earnings
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 139,071,000 101,159,000 22,646,000 28,707,000 1,436,400,000 263,136,000 91,994,000
Dec 2025 140,636,000 101,973,000 39,908,000 41,149,000 1,406,019,000 362,578,000 96,443,000
Sep 2025 131,872,000 91,282,000 23,112,000 19,137,000 1,367,787,000 315,573,000 110,120,000
Jun 2025 130,164,000 89,769,000 14,312,000 -980,000 1,344,104,000 219,499,000 123,047,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$136,307,000
Investing CF
$-9,209,000
Financing CF
$-4,222,000
CapEx
$-9,677,000
Dividends Paid
Buybacks
EPS Diluted TTM
$0.83
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-377,630,000
Inventory
$20,546,000
Receivables
$44,660,000
ST Investments
$50,311,000
EBIT TTM
$61,937,000
Pretax Income TTM
$68,201,000
Interest Exp TTM
$0
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$561,900,032
EBITDA
$111,304,000
Free Cash Flow
$99,944,376
Enterprise Value
$4,335,624,192
Total Cash
$485,232,000
Total Debt
$40,107,000
Shares Out
79,792,647
Trailing EPS
$1.08
Book Value
$16.50
ROE
8.8%
ROA
4.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 517,145,000 78,282,000 66,353,000 1,406,019,000 96,443,000 136,307,000
Dec 2024 445,764,000 19,510,000 24,138,000 1,300,035,000 124,069,000 75,096,000
Dec 2023 361,051,000 -17,446,000 -74,404,000 1,114,906,000 70,804,000 44,222,000
Dec 2022 296,536,000 -35,340,000 -36,560,000 1,156,422,000 81,222,000 7,535,000

TTM Snapshot

Revenues TTM
$341,930,000
NetIncome TTM
$-37,315,000
OpCashFlow TTM
$0
Assets (Latest)
$1,300,035,000
Forward EPS
$1.89

Peers — same industry

TickerNameMarket CapLastDaily %
CAI Caris Life Sciences, Inc. $4.41B $15.59
LFST LifeStance Health Group, Inc. $4.15B $10.86
CELC Celcuity Inc. $4.06B $83.26
CON Concentra Group Holdings Parent, Inc. $4.04B $31.61
RDNT RadNet, Inc. $4.98B $63.37

News headlines (Yahoo Finance, 1h cache)

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?
2026-07-31 10:06 · Yahoo
Veracyte Inc (VCYT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Launches ...
2026-07-31 05:03 · Yahoo
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
2026-07-30 22:00 · Yahoo
Veracyte Announces Second Quarter 2026 Financial Results
2026-07-30 20:05 · Yahoo
Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat
2026-07-30 13:17 · Yahoo
Veracyte to Participate in Upcoming Investor Conferences
2026-07-28 20:05 · Yahoo
Analysts Estimate TransMedics (TMDX) to Report a Decline in Earnings: What to Look Out for
2026-07-28 14:00 · Yahoo
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
2026-07-23 14:00 · Yahoo
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
2026-07-17 07:50 · Yahoo
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
2026-07-09 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.